Treatments

Cancer Mutation Reports and Targeted Therapy in China: What International Patients Should Prepare

Learn which cancer mutation reports, pathology, scans and treatment records international patients should prepare before discussing targeted therapy in China.

MedToChina Editorial Team · 9 min read · September 9, 2026

Cancer Mutation Reports and Targeted Therapy in China: What International Patients Should Prepare

Quick Summary

Targeted therapy can be relevant for some cancers when tumor biomarkers show drug-relevant changes, but a mutation report alone does not decide treatment. Chinese oncology teams may need pathology, imaging, staging, prior therapy history, performance status, lab results, medication lists and original testing details before they can understand whether a targeted therapy discussion is realistic. International patients should prepare a clean medical record package before traveling to China or contacting a service team. MedToChina can help patients submit basic information and send key records through WhatsApp so the next conversation is clearer, more efficient and medically cautious.

Why mutation reports matter before cancer care in China

International cancer patients often contact MedToChina after receiving a tumor gene panel, NGS report, liquid biopsy result, or biomarker report in their home country. Many ask a direct question: "Can I receive targeted therapy in China?" The question is understandable, but the real review is more complex.

A mutation report is only one part of cancer care. It may show EGFR, ALK, ROS1, BRAF, HER2, MET, RET, NTRK, KRAS, BRCA, MSI, TMB, PD-L1, HRD, or another biomarker, depending on cancer type and test design. Some findings may be linked to established treatments. Some may be linked to clinical trial discussion. Some may have unclear meaning. Some may not be useful for treatment decisions at all.

This is why the medical record package matters. A Chinese oncology team cannot interpret a biomarker result in isolation. The same mutation may have different meaning depending on tumor type, stage, prior therapies, tissue source, test quality, disease speed, organ function, symptoms and treatment goals. A patient with newly diagnosed lung cancer is different from a patient with heavily treated metastatic disease. A patient with a solid tumor is different from a patient with leukemia or lymphoma. A blood-based liquid biopsy is different from tissue testing. A report from 2022 may not reflect the current tumor biology in 2026.

For overseas patients, the goal before travel is not to make the final treatment decision on a website. The goal is to prepare enough reliable information so that later WhatsApp communication and hospital resource discussion can be based on facts rather than fragments.

What targeted therapy means in plain language

The National Cancer Institute describes targeted therapy as cancer treatment that focuses on proteins that help cancer cells grow, divide or spread. Many targeted therapies are small-molecule drugs or monoclonal antibodies. Some treatments are taken as pills, while others are given by infusion.

Targeted therapy is not the same as chemotherapy, immunotherapy, radiotherapy or surgery, although these treatments can sometimes be combined or sequenced. It is also not automatically gentler or more effective for every patient. Side effects may include diarrhea, liver problems, skin reactions, blood pressure changes, fatigue, mouth sores, bleeding or wound-healing issues, depending on the drug.

The word "targeted" can create unrealistic expectations. A target on a report does not mean that a drug is available, medically appropriate, affordable, safe with current organ function, or suitable after previous treatment. It also does not mean that the cancer will respond. Resistance can occur, and cancers may change over time.

For patients considering China, this means the mutation report should be treated as a starting point for structured review. It helps ask better questions, but it does not replace full oncology assessment.

Biomarker testing, NGS and liquid biopsy

Biomarker testing looks for genes, proteins or other substances that may help clinicians understand cancer behavior and treatment options. NCI notes that biomarker testing may also be called tumor testing, tumor genetic testing, genomic testing, molecular testing, molecular profiling or somatic testing.

Tests differ widely. A single-gene test answers a narrow question. A multi-gene panel checks many genes at the same time. Immunohistochemistry may measure proteins such as HER2 or PD-L1. FISH may detect certain gene rearrangements or amplifications. MSI or mismatch repair testing may matter in several cancers. Tumor mutational burden may be listed on some reports. Liquid biopsy uses blood or another body fluid to look for tumor-derived material and may be useful when tissue is difficult to obtain, but it has limits.

Patients should not assume that every NGS report is equivalent. A report should ideally show sample type, collection date, tumor content if tissue was used, test platform, genes included, detected alterations, allele frequency or copy number information when relevant, interpretation, therapy associations, limitations and lab information. If the report only says "mutation detected" without context, Chinese clinicians may need the original full report.

What Chinese oncology teams may want to review

Before discussing targeted therapy in China, international patients should prepare records in a way that answers both biological and clinical questions.

The first layer is diagnosis proof. This usually includes pathology reports, biopsy site, immunohistochemistry, cancer subtype and staging information. For some cancers, the original pathology slides or tissue block may be requested through a formal process after arrival or during hospital-based review.

The second layer is disease map. Imaging reports and DICOM files help show where the cancer is, how extensive it is and whether it has changed. CT, MRI, PET-CT, ultrasound, bone scan or endoscopy records may be relevant depending on cancer type. Written imaging reports are useful, but original DICOM files often provide more detail for radiology review.

The third layer is treatment history. Patients should list surgery, chemotherapy, radiotherapy, immunotherapy, targeted therapy, hormone therapy, cell therapy, local ablation and clinical trial exposure. Include drug names, doses if available, start and stop dates, reason for stopping and side effects. For targeted therapy, progression while taking a drug is very different from stopping because of toxicity or access issues.

The fourth layer is current fitness for treatment. Recent blood counts, liver and kidney function, coagulation, infection markers, heart history, medication list, allergies, weight loss, pain, appetite, mobility and recent hospitalizations may influence whether travel or treatment is realistic. Patients with oxygen needs, unstable symptoms or severe organ dysfunction may need local stabilization before considering international travel.

The fifth layer is the mutation report itself. Send the full report, not only a screenshot. If several tests were done over time, send all of them and label each by date and sample source. If tumor tissue and liquid biopsy results differ, do not try to simplify them into one sentence. Differences can be clinically important.

How to read a mutation report cautiously

Mutation reports often use language that is difficult for patients. They may list variants, fusions, amplifications, protein expression, microsatellite status, tumor mutational burden, tumor fraction, variant allele frequency and therapy associations. Some reports include evidence levels or categories.

The Association for Molecular Pathology, American Society of Clinical Oncology and College of American Pathologists have published a joint framework for interpreting and reporting sequence variants in cancer. The European Society for Medical Oncology also developed ESCAT, a framework that ranks genomic alterations by clinical actionability. The common idea is that not every genetic change carries the same level of evidence.

Patients should pay attention to three questions. First, is the alteration clearly related to this cancer type? Second, is there a treatment that clinicians use for this cancer and this biomarker? Third, is the patient clinically able to receive that treatment now?

Reports may include drug names approved in another country, drugs used in another cancer type, investigational therapies, or literature-based suggestions. That does not automatically mean the drug is available or appropriate in China. It also does not mean the patient should travel immediately. The report needs to be interpreted together with pathology, imaging, prior therapy and current condition.

Records to prepare before WhatsApp communication

A useful first message should be specific but not overloaded. Include age, nationality, current country, diagnosis, cancer stage if known, current symptoms, recent treatment, available mutation report, and the main question you want to discuss about care in China. If you have a preferred city such as Beijing, Shanghai or Guangzhou, mention it. If you have a travel window or companion need, include that as well.

Then prepare a folder with the following records:

One-page cancer summary.
Pathology report and immunohistochemistry.
Full mutation, biomarker or NGS report.
Recent imaging reports and DICOM files when available.
Treatment timeline with drug names and dates.
Recent lab results, especially blood count, liver and kidney function.
Current medication list, allergies and major medical history.
Discharge summaries or operation notes.
Translation of key records if they are not in English or Chinese.
Questions about travel, payment, stay length and follow-up.

If you are from the United States, Canada, the United Kingdom, Australia, the Middle East, Southeast Asia or Africa, your records may follow different local formats. That is fine. The priority is clarity: dates, diagnosis, source of tissue, test type, treatment history and current condition.

China-specific planning points

China has major oncology hospitals, Grade 3A public hospitals, international departments, private medical facilities and specialized centers in cities such as Beijing, Shanghai and Guangzhou. For international patients, the practical pathway usually starts with records and administrative information. Hospital resource discussion should happen after the support team understands diagnosis, goals, records, budget range, language needs and travel constraints.

Patients should also understand payment and documentation expectations. Many hospitals may require prepayment or deposits before admission or procedures. International insurance may not pay a Chinese hospital directly. Patients may need itemized receipts, discharge summaries, prescriptions and translated documents for reimbursement or local follow-up.

Travel planning matters in oncology. Some patients can attend outpatient evaluation. Others may need inpatient care, repeated imaging, biopsy, infusion visits, toxicity monitoring or treatment cycles. A short trip may not be suitable for complex disease. Ask what records are needed before travel, what information may change after in-person assessment, and what follow-up may be needed after returning home.

Common mistakes patients should avoid

The first mistake is sending only the mutation page without pathology and imaging. A gene result needs cancer context.

The second mistake is assuming that a liquid biopsy replaces all tissue information. Liquid biopsy can be useful, but a negative or partial result may not tell the full story.

The third mistake is focusing only on one drug name. Oncology decisions often depend on line of therapy, prior resistance, organ function, symptoms, treatment intent and available monitoring.

The fourth mistake is ignoring translation accuracy. A wrong biomarker name, sample date, dose, tumor site or side of the body can create confusion.

The fifth mistake is planning travel before confirming basic administrative and medical questions. Patients should clarify records, payment expectations, city preference, stay length and return-home care before making major travel decisions.

FAQ

Does a mutation report mean I can receive targeted therapy in China?

No. A mutation report helps guide discussion, but treatment decisions require oncology review of cancer type, stage, prior therapies, current condition, drug access, safety and patient goals.

Should I send tissue NGS or liquid biopsy?

Send both if you have them. Label each report by date and sample source. If only one is available, send the full report and explain whether it came from tumor tissue, blood or another sample.

What if my report is not in English or Chinese?

A careful translation is recommended for key records. Biomarker names, drug names, dates, doses and pathology terms should be translated accurately.

Can MedToChina tell me which targeted drug I should take?

No. MedToChina does not provide diagnosis or treatment decisions. We help patients organize information, submit records and communicate through WhatsApp before later service discussion.

What should I prepare before contacting MedToChina?

Prepare a short cancer summary, pathology, mutation report, recent imaging, treatment history, recent labs, medication list, travel timing and your main question about receiving care in China.

Can targeted therapy replace surgery, chemotherapy or immunotherapy?

Sometimes targeted therapy is part of a treatment plan, but it does not replace other treatments for every patient. Oncology decisions depend on the cancer and the individual situation.

Related MedToChina Resources

WhatsApp CTA

If you have a cancer mutation report and are considering treatment in China, submit your basic information or send your key records through WhatsApp. MedToChina can help you organize the record package and clarify what questions should be discussed before travel planning.

Medical Disclaimer

This article is for educational and planning purposes only. It does not provide medical diagnosis, treatment recommendation, visa advice, legal advice, or any assurance that a drug, clinical trial, hospital document or medical service will be available. International patients should consult licensed oncologists and official institutions before making medical or travel decisions.